Tuesday, 28 October 2025
  
Login

Australia's most trusted
source of pharma news

Tuesday, 28 October 2025
News

Takeda snaps up oncology hopefuls

Posted 27 October 2025 PM

Takeda will spend up to US$11.5 billion (AUD$17.5 billion) on the rights to three cancer drugs from Chinese biotech Innovent Biologics.

The Japanese pharma has signed a licensing and collaboration agreement for the development, manufacturing and commercialisation of two late-stage oncology medicines, IBI363 and IBI343, worldwide outside Greater China, as well as an exclusive option to license global rights outside Greater China for an early stage investigational medicine, IBI3001.

To see the whole article, please login

Popular

First PBS listing for Nov lands
Local exec wins Aussie GM role
Ex-Aussie MD reveals new role
Takeda snaps up oncology hopefuls
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (12)

Clinical & Medical, R&D (5)

Regulatory, Pharmacovigilance & QA (3)

Other (10)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home